Skip to main content

Professor James Chalmers

Professor (Clinical), Molecular and Clinical Medicine
School of Medicine
University of Dundee School of Medicine
Dundee, Scotland, United Kingdom

Professor James Chalmers

Related Videos

Can you discuss the current burden of NCFBE for patients and the healthcare system, in general, especially in regions globally—U.S., Europe, and Japan—where we see high disease burden, increasing prevalence, and profoundly impaired quality of life?

Can you discuss the current burden of NCFBE for patients and the healthcare system, in general, especially in regions globally—U.S., Europe, and Japan—where we see high disease burden, increasing prevalence, and profoundly impaired quality of life?

Professor Chalmers, can you share your focus on new therapeutic strategies for non-CF bronchiectasis and what key topics you’ll address in the iQ&A Bronchiectasis Pulmonary Medicine Intelligence Zone?

Professor Chalmers, can you share your focus on new therapeutic strategies for non-CF bronchiectasis and what key topics you’ll address in the iQ&A Bronchiectasis Pulmonary Medicine Intelligence Zone?

Can you explain the role of neutrophil serine proteases in NCFBE inflammation and how DPP-1 inhibition with brensocatib reduces NSP activity, mitigating progressive pulmonary inflammation?

Can you explain the role of neutrophil serine proteases in NCFBE inflammation and how DPP-1 inhibition with brensocatib reduces NSP activity, mitigating progressive pulmonary inflammation?

Given brensocatib’s recognition as a breakthrough in NCFBE care, how do you envision its role in current management and its integration into near-future treatment strategies for this progressive condition?

Given brensocatib’s recognition as a breakthrough in NCFBE care, how do you envision its role in current management and its integration into near-future treatment strategies for this progressive condition?

Before discussing WILLOW and ASPEN, what clinical biomarkers and symptomatic endpoints were prioritized to fully assess brensocatib’s efficacy, disease-modifying potential, and impact on quality of life?

Before discussing WILLOW and ASPEN, what clinical biomarkers and symptomatic endpoints were prioritized to fully assess brensocatib’s efficacy, disease-modifying potential, and impact on quality of life?

Can you outline the Phase 2 WILLOW trial design and results for brensocatib in NCFBE, including key efficacy and safety endpoints? Did the study demonstrate improvements in quality of life for participants?

Can you outline the Phase 2 WILLOW trial design and results for brensocatib in NCFBE, including key efficacy and safety endpoints? Did the study demonstrate improvements in quality of life for participants?

Are we entering a new therapeutic era for NCFBE with agents like brensocatib, recently approved to target neutrophil-driven inflammation central to the disease’s pathobiology?

Are we entering a new therapeutic era for NCFBE with agents like brensocatib, recently approved to target neutrophil-driven inflammation central to the disease’s pathobiology?

Based on WILLOW results in NCFBE, which positive signals—fewer exacerbations, better quality of life, reduced antibiotic use—did you aim to further evaluate and expand upon in the Phase 3 ASPEN trial?

Based on WILLOW results in NCFBE, which positive signals—fewer exacerbations, better quality of life, reduced antibiotic use—did you aim to further evaluate and expand upon in the Phase 3 ASPEN trial?

Given NCFBE’s heterogeneity and global prevalence, what are its key etiologies—particularly chronic infection—and how does recognizing these factors enhance detection, treatment, and confirmation of this severe pulmonary condition?

Given NCFBE’s heterogeneity and global prevalence, what are its key etiologies—particularly chronic infection—and how does recognizing these factors enhance detection, treatment, and confirmation of this severe pulmonary condition?